CDDF Multi-Stakeholder Workshop
Histology-independent Drug Development – Is this the future for cancer drugs?
14 – 15 November 2022, Hybrid Workshop
Recordings
SESSION 1: LESSONS LEARNED FROM PREVIOUS TRIALS - SUCCESSES AND FAILURES
Introduction / overview of successes: Alastair Greystoke (Newcaslte University, UK)
Regulatory perspective: Elias Pean (EMA, NL)
Moving from experimental phase to evidence-based practice, a payer’s perspective: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani (CZ, NL) – the speaker didn’t give consent to share the presentation
Session1: Panel discussion
SESSION 2: BIOMARKER DEVELOPMENT AND OPTIMISATION
SESSION 3: TRIALS DESIGN - BASKET OR UMBRELLA FOR OPTIMAL PROGRESS
Regulatory perspective: Dr Theodor Framke (EMA, NL) – the speaker didn’t give his consent to share the presentation
Academic perspective: Prof Lucinda Billingham (University of Birmingham, UK)
Early phase side of drug development – Industry perspective: Richardus Vonk (Bayer, DE)
Session 3: Panel discussion